Skip to main content

Table 1 Target volume doses for the TROG 17.03 LARK clinical trial. TD = Target Dose (prescribed dose). RVR = Remaining Volume at Risk

From: Study protocol of the LARK (TROG 17.03) clinical trial: a phase II trial investigating the dosimetric impact of Liver Ablative Radiotherapy using Kilovoltage intrafraction monitoring

LARK Target Volume Doses
Standardised Name Constraint Per Protocol Minor Variation Major Variation
PTVs around GTVs PTVs around Non-GTV CTVsa PTVs around GTVs PTVs around Non-GTV CTVsa PTVs around GTVs PTVs around Non-GTV CTVsa
GTV D100% ≥100% of the TD 95–100% of the TD ≤95% of the TD
PTV Dmax (0.03 cc) 120–140% of the TD 140–150% of the TD or 110–120% of the TD ≥150% of the TD or ≤ 110% of the TD
D95% 95–105% of the TD 90–95% or 105–110% of the TD, and > 25 Gy 85–95% or 105–115% of the TD, and > 25 Gy ≤90% or ≥110% of the TD, or ≤ 25 Gy ≤85% or ≥115% of the TD, or ≤ 25Gy
RVR Dmax (0.03 cc) ≤120% of the TD ≥120% of the TD
  1. a Non-GTV CTVs represents regions at high risk for microscopic disease, including non-tumour vascular thrombi, prior TACE sites, or adjacent RFA or other ablation sites. Treatment of these high-risk sites are permitted